{"ticker": {"uuid": "de333d2d-003c-42ae-8c7c-9d4b3669dbe9", "symbol": "N1BI34", "name": "Neurocrine Biosciences, Inc.", "exchange": "SAO", "country": "BR", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "Neurocrine Biosciences chief legal officer sells $1.79m in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPWnlxbXZ0amJyY1E4THNBMVJhOHlQb3NLdTdwbVFBNm5vdTlXTURmS1VlUmwxei1qOVNRc0dZcW9NeHdSSldfVmxpZzNDWC1zaDE4djNLeXNEUUxuWm1HenpERzczREVzX3o5eXg2azE1cjctbmJkdmNoX1J5RlZldnpCaUx6SWpRc0VNbEZYQTRkVmRxQmdrcTA2bG9hWVpvMU5HWVhveUFZUFpBM25BdnpVTkdENlZRV2hCMXkyVE4wa1RheUE?oc=5", "source_name": "Investing.com", "published_at": "2026-07-13T20:38:38+00:00", "published_display": "13 Jul 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences chief regulatory officer sells $2.6m stock By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNRHR6T3NDTmNQdndWdkp5TUtWWDFtQ0Z6ZmlSUFJnTGg2SktPYUI0YS1FX2cwbDI0dE9lUnJaNmEyZmJrUTl2V3dWWmlwRnJJeXFESW9pMEd0dXhhWk44STRoZTl0dXZoT2tsd092cjVWOHVEa3poNHZZR3JxR3RfaVR1MEJxbi1mX2IydTUtcU1VNGNEblNNcXdsWXZTd1Y3ZnZjRkFNVVk0cjlhV1c5bFpzOFF2UW9zVHFIazQ1MG1OQQ?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-07-09T23:12:59+00:00", "published_display": "09 Jul 2026 23:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences stock hits all-time high at 176.1 USD", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPOTB6a0VqaXlfUDlFN0dFV2czYmtRWm5lckN3RGtDNExveGUtUHk4WnBpRVRhajM1em1pRE1jeWlTazNKQ3d5MGZXdUNYZFR3TU92em5jaG4tdDN1Qk1hOGJFd2hJbzFZTjJZaVVsSTZNaTd6Nzlsb2lteFk2UjdkUThMUnlaV1RuOG43Wm1nR0VoWTBiSWl4Qi1xbjVLVGozN3RxM2RVM1pmeF9hQWpyNFZrMlh6dw?oc=5", "source_name": "Investing.com", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences Inc (NBIX) Stock Up 3.9% and Still Underv", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AJBVV95cUxPY1FnaGJvVTZVT0lsMV9VTFI1SUQzN29aanZxUkYtTW04dmdIRHRqTlVUcXMzMXFqdzFfWXV0UjBrVi1RS0YzNldUTVBZZ3BETXhwNXBqVDJfZlZzQ1Ayb0dQTGZCZDNYcDV6am04LUVTRlFEaU9uYVRNX2l2bzJrd0FMNVlMV1RUSUZkUW1ZZ2I1ZGIzblpUNnpFbnBJaWsxQ0tJQVNObkxuWlZzMnktb0lQYnpwRE94UUVLbndNaF8xZjZiWWVYNkNiWDNmMmc4bzEtUDV2Wk9zd2JJXzh4Q2U5MTdmOXVmaC1hMjB5MnktVHFDOWdTbHVvMjBIMEhueGRPLXM1SHRSaWZCS0pfRnJNWXFFTFJSQnlCN2ktZFduR0w2YmNST2d5SlM5dTlrYm4zRTNNWk1xVXRxOHpPRlFVVk9TMzNUMm5fRlprVXRzSUJsWEl4ejJDQVluWGJ1?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNczNFMEx3Q0wwdC1hWUNqT3c5WmwzYUhOMkhYOEpuOEZCZU5QcmVfR01OR3ZvaC1LY0xwOE80VHduRzNTZExCbEZkaE1hREw4TnlXVTdIZnN3cC1PeEFlZlBHYTh4RV9QTjBfTkw3ODNjbFczTDZpTzRjZm9wM25XdHBDdDBUbmJhaUlwWkYwM2N1OEVGdmZLSzd3RldNNnhDRjNyWWNSTTBUWmg1SmE0bGhZOVI4cXZqR3YzV2YzSWE?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences Reports First-Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQTkY0VWxfSGVMMGh4c0Y1Q05OOERWbUV4UlNpQ1lWZ1BIYVlTQzhYVXFZdElxLTl3NjJZNWxQQ2VEbE9OY2dEaUc0RHRZY1lfQVVCbEZDQ2g0NmF5eHpRUWI4Z1pFaVNPVzhvdndkcms0ZUxUcUhCLXl6X0o0WFc1Q2FOTUNQM083SmRaZjZfaFB0RHY0TFY1YXNhbzdJS1RNZ3FZWVZEZEsxTHVjLVFUOUtOV1NsTmlnRWVKWFNZbUk?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Neurocrine Biosciences chief legal officer sells $1.79m in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPWnlxbXZ0amJyY1E4THNBMVJhOHlQb3NLdTdwbVFBNm5vdTlXTURmS1VlUmwxei1qOVNRc0dZcW9NeHdSSldfVmxpZzNDWC1zaDE4djNLeXNEUUxuWm1HenpERzczREVzX3o5eXg2azE1cjctbmJkdmNoX1J5RlZldnpCaUx6SWpRc0VNbEZYQTRkVmRxQmdrcTA2bG9hWVpvMU5HWVhveUFZUFpBM25BdnpVTkdENlZRV2hCMXkyVE4wa1RheUE?oc=5", "source_name": "Investing.com", "published_at": "2026-07-13T20:38:38+00:00", "published_display": "13 Jul 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences chief regulatory officer sells $2.6m stock By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNRHR6T3NDTmNQdndWdkp5TUtWWDFtQ0Z6ZmlSUFJnTGg2SktPYUI0YS1FX2cwbDI0dE9lUnJaNmEyZmJrUTl2V3dWWmlwRnJJeXFESW9pMEd0dXhhWk44STRoZTl0dXZoT2tsd092cjVWOHVEa3poNHZZR3JxR3RfaVR1MEJxbi1mX2IydTUtcU1VNGNEblNNcXdsWXZTd1Y3ZnZjRkFNVVk0cjlhV1c5bFpzOFF2UW9zVHFIazQ1MG1OQQ?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-07-09T23:12:59+00:00", "published_display": "09 Jul 2026 23:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences stock hits all-time high at 176.1 USD", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPOTB6a0VqaXlfUDlFN0dFV2czYmtRWm5lckN3RGtDNExveGUtUHk4WnBpRVRhajM1em1pRE1jeWlTazNKQ3d5MGZXdUNYZFR3TU92em5jaG4tdDN1Qk1hOGJFd2hJbzFZTjJZaVVsSTZNaTd6Nzlsb2lteFk2UjdkUThMUnlaV1RuOG43Wm1nR0VoWTBiSWl4Qi1xbjVLVGozN3RxM2RVM1pmeF9hQWpyNFZrMlh6dw?oc=5", "source_name": "Investing.com", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences Inc (NBIX) Stock Up 3.9% and Still Underv", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AJBVV95cUxPY1FnaGJvVTZVT0lsMV9VTFI1SUQzN29aanZxUkYtTW04dmdIRHRqTlVUcXMzMXFqdzFfWXV0UjBrVi1RS0YzNldUTVBZZ3BETXhwNXBqVDJfZlZzQ1Ayb0dQTGZCZDNYcDV6am04LUVTRlFEaU9uYVRNX2l2bzJrd0FMNVlMV1RUSUZkUW1ZZ2I1ZGIzblpUNnpFbnBJaWsxQ0tJQVNObkxuWlZzMnktb0lQYnpwRE94UUVLbndNaF8xZjZiWWVYNkNiWDNmMmc4bzEtUDV2Wk9zd2JJXzh4Q2U5MTdmOXVmaC1hMjB5MnktVHFDOWdTbHVvMjBIMEhueGRPLXM1SHRSaWZCS0pfRnJNWXFFTFJSQnlCN2ktZFduR0w2YmNST2d5SlM5dTlrYm4zRTNNWk1xVXRxOHpPRlFVVk9TMzNUMm5fRlprVXRzSUJsWEl4ejJDQVluWGJ1?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNczNFMEx3Q0wwdC1hWUNqT3c5WmwzYUhOMkhYOEpuOEZCZU5QcmVfR01OR3ZvaC1LY0xwOE80VHduRzNTZExCbEZkaE1hREw4TnlXVTdIZnN3cC1PeEFlZlBHYTh4RV9QTjBfTkw3ODNjbFczTDZpTzRjZm9wM25XdHBDdDBUbmJhaUlwWkYwM2N1OEVGdmZLSzd3RldNNnhDRjNyWWNSTTBUWmg1SmE0bGhZOVI4cXZqR3YzV2YzSWE?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurocrine Biosciences Reports First-Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQTkY0VWxfSGVMMGh4c0Y1Q05OOERWbUV4UlNpQ1lWZ1BIYVlTQzhYVXFZdElxLTl3NjJZNWxQQ2VEbE9OY2dEaUc0RHRZY1lfQVVCbEZDQ2g0NmF5eHpRUWI4Z1pFaVNPVzhvdndkcms0ZUxUcUhCLXl6X0o0WFc1Q2FOTUNQM083SmRaZjZfaFB0RHY0TFY1YXNhbzdJS1RNZ3FZWVZEZEsxTHVjLVFUOUtOV1NsTmlnRWVKWFNZbUk?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 42, "total_relevant": 6, "sentiment_summary": {"positive": 0, "negative": 0, "neutral": 6, "score": 50, "total": 6, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 68, "events": [{"event": "general", "label": "Market update", "weight": 1.65, "count": 3}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}, {"event": "earnings", "label": "Earnings", "weight": 0.55, "count": 1}], "positive_events": 0, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 45.05, "latest_week": "2026-07-10", "one_week_move": 0.4, "four_week_move": 4.6, "twelve_week_move": 38.0, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.000483, "market_dynamics_buy_signal": false, "relative_strength": 9.283366, "fair_value_gap": 28.8, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 54.6961, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.4% over one week, +4.6% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 44, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Investing.com", "count": 2}, {"label": "PR Newswire", "count": 2}, {"label": "Investing.com Canada", "count": 1}, {"label": "GuruFocus", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 6}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 3}, {"label": "Regulatory and legal", "count": 1}, {"label": "Deals and strategy", "count": 1}, {"label": "Earnings", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "68/100 classification confidence."}, {"label": "Company focus", "value": "6", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+0.4% over one week, +4.6% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Neurocrine Biosciences chief legal officer sells $1.79m in stock"}], "updated_at": "2026-07-17T18:58:56.713863+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}